OSI-906 (Linsitinib)

Catalog No.S1091

OSI-906 (Linsitinib) Chemical Structure

Molecular Weight(MW): 421.49

OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Cancer Res 2013 73, 834-843. OSI-906 (Linsitinib) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. OSI-906 (Linsitinib) purchased from Selleck.

  •  

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    OSI-906 (Linsitinib) purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
Abl [1]
(Cell-free assay)
ALK [1]
(Cell-free assay)
35 nM 75 nM 75 nM >10 μM >10 μM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk M1zQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\ROWdKSzVyPUCuNFI5ODZizszN MYrTRW5ITVJ?
KS-1 Ml3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEftbYdKSzVyPUCuNFM5OzVizszN M3y2WXNCVkeHUh?=
TE-11 M{X1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMEe4NlIh|ryP NWfPeFQ4W0GQR1XS
EW-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMEi1PFUh|ryP MkLRV2FPT0WU
HMV-II M3TlcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHHe41KSzVyPUCuNFg5PDZizszN NEHBSItUSU6JRWK=
COLO-205 NYLLOllRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV63eplbUUN3ME2wMlExPDV2IN88US=> NWPsUZQxW0GQR1XS
ES1 MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:3TWM2OD1yLkGwOlk3KM7:TR?= MXTTRW5ITVJ?
GDM-1 M4[wNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLsTWM2OD1yLkGzOlczKM7:TR?= MXTTRW5ITVJ?
ML-2 NYXXNWRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnDeodIUUN3ME2wMlE2QDl4IN88US=> NIjx[JlUSU6JRWK=
Saos-2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMU[1NlYh|ryP NFHDbZhUSU6JRWK=
NCI-H1355 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr2Z|BKSzVyPUCuNVgyOzVizszN NYnnWWxoW0GQR1XS
G-401 NG\seY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELmdGNKSzVyPUCuNVgzOyEQvF2= NWL1[|JTW0GQR1XS
EW-16 MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojvTWM2OD1yLkG4O|c4KM7:TR?= NGjMdY1USU6JRWK=
EW-7 NEnEbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;uTWM2OD1yLkG4PFgyKM7:TR?= NXPvWnc2W0GQR1XS
NCI-H727 MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMUm3PVQh|ryP M{nFbnNCVkeHUh?=
LCLC-97TM1 NGXtOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTHcm1lUUN3ME2wMlIxQTV3IN88US=> Mlq2V2FPT0WU
NCI-H650 M37qe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMkGzPFQh|ryP NVv5fWo3W0GQR1XS
NCI-H2122 Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDQVYtKSzVyPUCuNlMzQTlizszN MYTTRW5ITVJ?
SK-N-DZ M2HQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrKT2hKSzVyPUCuNlM3QThizszN MmDYV2FPT0WU
HT-29 M1TaTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:2OGlEPTB;MD6yOFI1QCEQvF2= NHfucnNUSU6JRWK=
LB771-HNC M2K0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMkW5NVUh|ryP M37tPXNCVkeHUh?=
HT-144 NVGzfFRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXiyPJdyUUN3ME2wMlI3OTlzIN88US=> MkjMV2FPT0WU
LAN-6 MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;RPVBUUUN3ME2wMlI3OzR6IN88US=> MnrCV2FPT0WU
EW-18 NH7hWIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwMkewNFEh|ryP MXvTRW5ITVJ?
LS-1034 NHfNSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;uSHhKSzVyPUCuNlcyOzJizszN NUX4fZlqW0GQR1XS
EW-11 M3XyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLFTWM2OD1yLkK4OFMzKM7:TR?= NIjmNXlUSU6JRWK=
SNU-C1 NETPdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjnVnFKSzVyPUCuNlk{OTNizszN MlKyV2FPT0WU
RS4-11 NGrWdFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPF[21VUUN3ME2wMlM{PzV6IN88US=> NFvZW2RUSU6JRWK=
ES4 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUj3VmpjUUN3ME2wMlQyODN6IN88US=> MXzTRW5ITVJ?
COLO-320-HSR M1XFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nOPGlEPTB;MD60NVM3QCEQvF2= Mn7KV2FPT0WU
NB10 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjwVFlKSzVyPUCuOFU1OzdizszN NWj6bGhQW0GQR1XS
BFTC-905 Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXviVHJbUUN3ME2wMlQ3PzV6IN88US=> NXy2WYlxW0GQR1XS
A375 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ftVWlEPTB;MD60O|YyPyEQvF2= M4W3SHNCVkeHUh?=
SJRH30 NGe0d5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLrOI5vUUN3ME2wMlUxQDJ{IN88US=> NFvO[4JUSU6JRWK=
NOS-1 NGXRVXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfkemt6UUN3ME2wMlUzOjZ5IN88US=> MojPV2FPT0WU
SIG-M5 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjp[3FQUUN3ME2wMlU{PTV5IN88US=> MVnTRW5ITVJ?
DOK M3:0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDrTWM2OD1yLkW1OkDPxE1? MX\TRW5ITVJ?
NB69 Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fOXWlEPTB;MD61PFI2PyEQvF2= M{i3W3NCVkeHUh?=
SK-NEP-1 NITLeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvm[VRKSzVyPUCuOlAzOzZizszN M1nnVXNCVkeHUh?=
SK-MM-2 MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[0SJdKSzVyPUCuOlU1QTFizszN NILI[|VUSU6JRWK=
NCI-H358 M1[1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO2b4RRUUN3ME2wMlY4ODh{IN88US=> MWrTRW5ITVJ?
RH-1 NYXLd4F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XYTGlEPTB;MD63OFg2QSEQvF2= M{XTcHNCVkeHUh?=
NH-12 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;OTWM2OD1yLke2NFQ3KM7:TR?= NGnyc|RUSU6JRWK=
TE-12 M4TvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwN{[0PFYh|ryP NIe5ZmJUSU6JRWK=
COLO-668 NHPSU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f0VWlEPTB;MD64OFY3PiEQvF2= MYrTRW5ITVJ?
PANC-08-13 M1fVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnPOlRKSzVyPUCuPFY{PzdizszN M1HDUnNCVkeHUh?=
HCC2998 M1rzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;sVndKSzVyPUCuPFgzPjNizszN MnrCV2FPT0WU
ABC-1 MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvyTWM2OD1yLkmwN|UzKM7:TR?= M1HqTnNCVkeHUh?=
ES6 NX[yeo1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L1V2lEPTB;MD65NVA3PiEQvF2= MlexV2FPT0WU
SNU-387 NHvVb3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFKwR3ZKSzVyPUCuPVk{QTNizszN NFjaenNUSU6JRWK=
CMK NHXzS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmCxTWM2OD1yLkm5PVI6KM7:TR?= Moj5V2FPT0WU
SJSA-1 NVHwfW5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4WxOWlEPTB;MT6wN|Y2OyEQvF2= NGLYflVUSU6JRWK=
SIMA MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrTTWM2OD1zLkC2PFI2KM7:TR?= NICwdI5USU6JRWK=
ES3 Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTFwMUKyPVch|ryP MWjTRW5ITVJ?
IGROV-1 NH3yWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrxT5ZKSzVyPUGuNVU1PDRizszN NGfQcYhUSU6JRWK=
MEL-JUSO MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjJbFJKSzVyPUGuNVU4PTlizszN MUfTRW5ITVJ?
T84 NHXu[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[yTWM2OD1zLkKwPVE1KM7:TR?= Mn7FV2FPT0WU
CAL-85-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFwMkOxN|gh|ryP M4rEUXNCVkeHUh?=
RD NGT0NpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK4U45KSzVyPUGuNlY1PTVizszN NVfOTFNGW0GQR1XS
TE-8 NV\4ZlE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj6XWNHUUN3ME2xMlMyPDZ{IN88US=> NVzHTXJLW0GQR1XS
L-363 M131fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPEOYlKSzVyPUGuN|QzODhizszN MoDsV2FPT0WU
EKVX M3vqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;DeGw4UUN3ME2xMlM1PTZ6IN88US=> MULTRW5ITVJ?
SK-MEL-3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTFwNEi1OVYh|ryP NGH1cYFUSU6JRWK=
TGBC24TKB MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS3[HA2UUN3ME2xMlUxOTl|IN88US=> MonFV2FPT0WU
NCI-H1770 NF;CZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnaR3VKSzVyPUGuOVEyOTNizszN NWj5RZFUW0GQR1XS
HuH-7 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYOwcJg{UUN3ME2xMlYxODl6IN88US=> M3HISXNCVkeHUh?=
HL-60 M1PqNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTFwNk[5Nlgh|ryP MYrTRW5ITVJ?
TE-1 M2jJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFwN{C5OFUh|ryP M4fk[3NCVkeHUh?=
LC-2-ad MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTFwN{O4PFch|ryP M{P5bnNCVkeHUh?=
LB647-SCLC MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjHcmVWUUN3ME2xMlc3PTh|IN88US=> MkPJV2FPT0WU
NCI-H2171 NHLBdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvDTWM2OD1zLke3O|E3KM7:TR?= NIrReYlUSU6JRWK=
SK-PN-DW NYLF[JA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjBNWpvUUN3ME2xMlkyOjl6IN88US=> MoPnV2FPT0WU
MC-IXC NFjC[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\ydpJ2UUN3ME2xMlk5QThizszN NGP2fVJUSU6JRWK=
LS-513 NEPsb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTJwMEWzNFUh|ryP NVOxbo9QW0GQR1XS
EW-3 MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i5U2lEPTB;Mj6wPVg1PCEQvF2= M3fvXnNCVkeHUh?=
OPM-2 MlzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rTUGlEPTB;Mj6xNFIh|ryP M2PlUHNCVkeHUh?=
LP-1 M2\qN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq2cJdKSzVyPUKuNlU5ODdizszN NYHRfpRmW0GQR1XS
LU-134-A MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjHSY82UUN3ME2yMlI4PyEQvF2= NIXiVoRUSU6JRWK=
CP66-MEL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnLN|FmUUN3ME2yMlI6ODF2IN88US=> Mkm2V2FPT0WU
HCC1143 NXX1OphpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\YU2gzUUN3ME2yMlQ2OzZ6IN88US=> MYHTRW5ITVJ?
LOXIMVI NYPJTXdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\KT2R4UUN3ME2yMlYxOjFizszN NVHLPWZ6W0GQR1XS
TE-10 MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfld2JOUUN3ME2yMlcxQDN6IN88US=> NV24SmN3W0GQR1XS
NCI-H1882 NV75d3BGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJwN{WyNlch|ryP Mn62V2FPT0WU
CHP-126 NE\uT|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXxTWM2OD1{Lke2N|E4KM7:TR?= MlT6V2FPT0WU
NCI-H1623 MkTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmW4TWM2OD1{LkmyNFI1KM7:TR?= NFzJW|ZUSU6JRWK=
GB-1 MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rHbGlEPTB;Mj65N|QxPCEQvF2= NX7CSGRNW0GQR1XS
RCC10RGB MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrlTWM2OD1{Lkm1NlgyKM7:TR?= MYrTRW5ITVJ?
NCI-H2141 M3HNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJwOU[4PVYh|ryP NHuzVnZUSU6JRWK=
GI-ME-N MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{e5d2lEPTB;Mz6wNFU3PSEQvF2= NELOdm5USU6JRWK=
NCI-H526 M{P4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTNwMESwPFUh|ryP M{G0UXNCVkeHUh?=
NCI-H747 M2XEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTMXWVFUUN3ME2zMlA1QTl{IN88US=> MXTTRW5ITVJ?
SNU-423 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n0U2lEPTB;Mz6yNFMyOyEQvF2= NITRUI5USU6JRWK=
A427 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\udmlEPTB;Mz6yOVY6QSEQvF2= M1n6bnNCVkeHUh?=
CAL-12T NI[1bXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7he|ZKSzVyPUOuOFA4OTNizszN MkXyV2FPT0WU
LU-99A MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfTWItnUUN3ME2zMlQ4OTB3IN88US=> MU\TRW5ITVJ?
MS-1 NH2xeoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXXXJZLUUN3ME2zMlU{PDJ7IN88US=> NX:zOYNbW0GQR1XS
SK-LU-1 M2Lvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvMUVRKSzVyPUOuO|YzQTVizszN MWfTRW5ITVJ?
SW837 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHkR|lKSzVyPUOuO|Y{OzNizszN M4XtT3NCVkeHUh?=
ES8 MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzJTWM2OD1|LkizPFc4KM7:TR?= NH\DWJRUSU6JRWK=
MZ2-MEL M1rXfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;CWGNKSzVyPUOuPVIxQDZizszN MWfTRW5ITVJ?
TGW NEP1bWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXEd5h6UUN3ME20MlAyOzFzIN88US=> NV\1VYpjW0GQR1XS
GP5d MnPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDZTWM2OD12LkC1N|YzKM7:TR?= NUjBc3BjW0GQR1XS
BB49-HNC NHXLTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTRwMUWyNVMh|ryP M13hfnNCVkeHUh?=
NB13 NXHI[mhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTRwMk[4PFch|ryP M2K0cHNCVkeHUh?=
NTERA-S-cl-D1 M{LqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPtTWM2OD12LkK4OlE2KM7:TR?= NXTzZ5hEW0GQR1XS
NCI-H1648 M3vy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG3R2hKSzVyPUSuNlk5OTlizszN NV:weGNwW0GQR1XS
LCLC-103H NYjkenRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XoNGlEPTB;ND6zNlE6PSEQvF2= M17WdHNCVkeHUh?=
LS-411N MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTRwNES4PFUh|ryP NFnBZlFUSU6JRWK=
NCI-H1092 NEnYVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTZ[HRKSzVyPUSuOFU3QDdizszN NGK4dJlUSU6JRWK=
PANC-10-05 NVvWOVVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi4RnRKSzVyPUSuOlk5PCEQvF2= MYPTRW5ITVJ?
DK-MG MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fMcGlEPTB;ND64NFk{OyEQvF2= M2HZOHNCVkeHUh?=
OVCAR-5 M1ftdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfoTFhKSzVyPUSuPFEzOjZizszN M4r0U3NCVkeHUh?=
CAL-39 Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XoTmlEPTB;ND64O|Y4KM7:TR?= NFTFNHFUSU6JRWK=
TE-441-T NIrPRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTRwOUC1N|ch|ryP NWTHRmdmW0GQR1XS
MOLT-16 NWnPNJVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTRwOUWyOVMh|ryP NVnj[4FnW0GQR1XS
MCF7 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLIdJJKSzVyPUWuNVQ2OTdizszN MV3TRW5ITVJ?
CAPAN-1 NUfPTFFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzCU|J2UUN3ME21MlI2PzB5IN88US=> MWrTRW5ITVJ?
PSN1 MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTVwMkeyN|Uh|ryP MUfTRW5ITVJ?
NCI-H292 NVjoWmlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjYZmtDUUN3ME21MlMxODR2IN88US=> MYnTRW5ITVJ?
CPC-N NGTiPGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlG5TWM2OD13LkO5OFE6KM7:TR?= MX;TRW5ITVJ?
DoTc2-4510 Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq0fYNCUUN3ME21MlQ2OzdzIN88US=> Ml;yV2FPT0WU
LB1047-RCC NVOxT3VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrRTWM2OD13LkW1PVM{KM7:TR?= MlT1V2FPT0WU
MHH-ES-1 M{LQemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm3bIJ5UUN3ME21MlU6QTB5IN88US=> NFfrN2lUSU6JRWK=
NMC-G1 Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:1TmlEPTB;NT63NFIzPyEQvF2= MmWzV2FPT0WU
SW1710 MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\aeVJKSzVyPUWuO|Q4PTFizszN NV\3T29wW0GQR1XS
YAPC M4fVZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL6dpFKSzVyPUWuO|YzODFizszN M3PifHNCVkeHUh?=
22RV1 NGrheWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu5PZlKSzVyPUWuPFAxOTlizszN MlPxV2FPT0WU
COLO-679 M3js[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTVwOEi5OFgh|ryP NX3nfGxxW0GQR1XS
TCCSUP NFTWV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLyR|BTUUN3ME21Mlk{OjV7IN88US=> M4XHd3NCVkeHUh?=
C2BBe1 M{j0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\FdGlEPTB;NT65N|k4KM7:TR?= MXPTRW5ITVJ?
TE-15 MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTZwME[2NFUh|ryP M1GxfnNCVkeHUh?=
SCLC-21H MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjZV2NKSzVyPU[uNVA5PDNizszN NEnTZolUSU6JRWK=
EoL-1-cell NH\6fGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3hdG54UUN3ME22MlE3PTZ|IN88US=> NIDIS|JUSU6JRWK=
NKM-1 M4DaSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXtb49KSzVyPU[uNVY4OSEQvF2= M2fKZXNCVkeHUh?=
NCI-H1304 NY\YSGpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2frdmlEPTB;Nj6yO|QzQCEQvF2= NXy5WolzW0GQR1XS
NB6 NGPFW5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfBRmhKSzVyPU[uNlk3OjJizszN NHm3TWJUSU6JRWK=
NALM-6 NWXDVJdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrHfHdRUUN3ME22MlM{OjNizszN M2X3OnNCVkeHUh?=
NCI-H522 MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTZwM{OzNFYh|ryP MWDTRW5ITVJ?
MV-4-11 MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;UPVcxUUN3ME22MlM4ODd7IN88US=> M2nJRXNCVkeHUh?=
LB2241-RCC M1vzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTjTWM2OD14LkO4OlY4KM7:TR?= MoPnV2FPT0WU
NCI-H1417 NGO4VWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHZPFVrUUN3ME22MlQxQDR5IN88US=> NGHWUVNUSU6JRWK=
HT-1197 NFLKSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTZwNUexNlIh|ryP Mn60V2FPT0WU
P30-OHK NVnse5FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXMTWM2OD14Lk[yO|ch|ryP NX3tRmt5W0GQR1XS
ALL-PO M4nkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfaTWM2OD14LkexPVE3KM7:TR?= MmLKV2FPT0WU
OVCAR-4 M4PLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTZwN{W0NFUh|ryP MkH6V2FPT0WU
HCC2157 NHXHUoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTZwN{e0O|Uh|ryP NVjG[o5mW0GQR1XS
NCI-H838 M4ntOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PWdWlEPTB;Nj65OlQ6KM7:TR?= NVr2RohoW0GQR1XS
NCI-H1299 NHvNUoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzJTWM2OD14Lkm3NFkh|ryP MXjTRW5ITVJ?
SW954 NYTnV21TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzTUVRKSzVyPUeuNlAxPjhizszN MoG1V2FPT0WU
NCI-H441 NWLJ[3hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP3TWM2OD15LkO0NFY2KM7:TR?= MXrTRW5ITVJ?
SK-MEL-2 NHHk[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTdwNEizO|Mh|ryP M{PteXNCVkeHUh?=
KARPAS-45 NYrxO4ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TKOmlEPTB;Nz62OVkzQSEQvF2= MUTTRW5ITVJ?
CAL-54 MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXESGVKSzVyPUeuPFI6PzdizszN MYTTRW5ITVJ?
KYSE-180 M1TYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPsTWM2OD15Lki4PVQyKM7:TR?= NInjUmFUSU6JRWK=
NCI-H187 NX70fnk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HUWGlEPTB;Nz65OVk1PyEQvF2= M1jBVnNCVkeHUh?=
RT-112 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRThwMEm2O|ch|ryP MX3TRW5ITVJ?
NCI-H1437 NEnn[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\l[mlEPTB;OD6wPVc6PSEQvF2= MV;TRW5ITVJ?
SNU-449 NXGzc4VIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3q5VWlEPTB;OD6yPFI4OiEQvF2= NEG5NZFUSU6JRWK=
HCC1187 NUPCXFBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRThwMkmzPVEh|ryP NE\MOWhUSU6JRWK=
NCI-H2030 MljPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPwT3NHUUN3ME24MlM4PzF2IN88US=> MVfTRW5ITVJ?
HuO-3N1 M125PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP6TWM2OD16LkO3PFQ1KM7:TR?= NXjIb3pEW0GQR1XS
COLO-792 NWrXWlV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrPVWFKSzVyPUiuOFE2OjdizszN MkjzV2FPT0WU
MIA-PaCa-2 NXLFO4hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRThwOEW1NFgh|ryP NVL4W5htW0GQR1XS
SK-N-FI M2XrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHJTWM2OD17LkC0NlUh|ryP NWnTelV[W0GQR1XS
MMAC-SF NH3yR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXNU5lSUUN3ME25MlA6PzVzIN88US=> NWDKWZk2W0GQR1XS
NCI-H28 NUThU5BYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX2TWM2OD17LkGwOFY6KM7:TR?= M33oV3NCVkeHUh?=
ETK-1 NYT3OJJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfVNo9KSzVyPUmuNlk6PzRizszN M{f0NnNCVkeHUh?=
NCI-H1993 M2n5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInQSlhKSzVyPUmuOFQzPjFizszN MkHNV2FPT0WU
no-11 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfkb5lUUUN3ME25MlQ4OTJizszN M1n5WXNCVkeHUh?=
ChaGo-K-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\STWM2OD17LkWxOVg{KM7:TR?= MnP3V2FPT0WU
NCCIT Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTlwNUOxOlkh|ryP NHvSPYZUSU6JRWK=
SAS MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXHbHlwUUN3ME2xNE4zPDhizszN NXmyT245W0GQR1XS
A673 MkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHBVGRKSzVyPUGwMlM4ODRizszN MonFV2FPT0WU
NCI-H1522 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7UU5BKSzVyPUGwMlM4ODdizszN NYexSFhXW0GQR1XS
NCI-H810 NIL2cW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzGWXFKSzVyPUGwMlM6ODdizszN NH7qN2RUSU6JRWK=
IST-MES1 MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFyLkS1OlQh|ryP Mn;NV2FPT0WU
GR-ST M3rKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnxV4VUUUN3ME2xNE42ODJ2IN88US=> NI\FTlJUSU6JRWK=
SUP-T1 NH7KfnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHI[oExUUN3ME2xNE44OzF5IN88US=> NYqxe3JHW0GQR1XS
NB5 NU\Qd4dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDmU41xUUN3ME2xNE46ODJ{IN88US=> MVjTRW5ITVJ?
MZ1-PC Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjSdGg3UUN3ME2xNE46PTdzIN88US=> M3vLOnNCVkeHUh?=
SK-CO-1 M{DK[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGCwfVVKSzVyPUGwMlk6OzFizszN NHTj[2pUSU6JRWK=
Capan-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPCWWdKSzVyPUGxMlMyQThizszN MUnTRW5ITVJ?
697 NEntVo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[0V5dKSzVyPUGxMlY4PTdizszN M2LaTnNCVkeHUh?=
REH M4XafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{e5ZmlEPTB;MUGuO|Q2OSEQvF2= NHztb|RUSU6JRWK=
GI-1 MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFzLki2NVUh|ryP MkLkV2FPT0WU
BB65-RCC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfY[2NKSzVyPUGyMlA6OTZizszN M2\YVXNCVkeHUh?=
NCI-H1651 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PKOGlEPTB;MUKuNlQ4QCEQvF2= M4XHNHNCVkeHUh?=
NCI-H1618 MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fLOmlEPTB;MUKuN|k4PiEQvF2= NFLLT|NUSU6JRWK=
NCI-H2081 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrzXXpKSzVyPUGyMlYyPDFizszN Mn3EV2FPT0WU
GCIY NVqzNY1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHETWM2OD1zMj63NlE{KM7:TR?= NXz0WJNjW0GQR1XS
NY NXHo[3hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{GzUGlEPTB;MUOuNFY1OyEQvF2= NIXXR|hUSU6JRWK=
PANC-03-27 MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LsUGlEPTB;MUOuNFgxPyEQvF2= MUHTRW5ITVJ?
BHY NYPndHBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vIWWlEPTB;MUOuNlEzOSEQvF2= NYnVTHl{W0GQR1XS
SK-OV-3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nQc2lEPTB;MUOuN|c3OyEQvF2= MV\TRW5ITVJ?
5637 MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\teo1KSzVyPUGzMlc4PTlizszN MkTEV2FPT0WU
LC-1F NVvxUIN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3W5cGlEPTB;MUSuNFM2PiEQvF2= NHHHeJNUSU6JRWK=
SNB75 M4[zZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYezd2NIUUN3ME2xOE4xOzh|IN88US=> NWfYfmhrW0GQR1XS
CHP-212 MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPyd2diUUN3ME2xOE4xPDZ2IN88US=> M1rCOnNCVkeHUh?=
HT-1376 NH:0WnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PoXGlEPTB;MUSuNVEzPiEQvF2= NGPibJZUSU6JRWK=
MONO-MAC-6 MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHNdohsUUN3ME2xOE4yPTB{IN88US=> NFv1emNUSU6JRWK=
CA46 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX73VXZlUUN3ME2xOE4yQDJ5IN88US=> MlLtV2FPT0WU
SCC-15 M2rKZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzIUGxKSzVyPUG0MlU2QDNizszN M1\MbnNCVkeHUh?=
ATN-1 Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmruTWM2OD1zND62OlI4KM7:TR?= MmS5V2FPT0WU
NCI-H2405 NFriZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnYPZVqUUN3ME2xOE45OTV5IN88US=> M2GyfnNCVkeHUh?=
NCI-H716 NGK2VplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;WNY5VUUN3ME2xOE45PDl|IN88US=> MmjxV2FPT0WU
SW620 M4\0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTF2LkmwNVQh|ryP MUfTRW5ITVJ?
NCI-H226 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPZTWM2OD1zND65NFg2KM7:TR?= MYTTRW5ITVJ?
SW962 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7hTWM2OD1zND65OFMzKM7:TR?= NVPy[otpW0GQR1XS
KYSE-150 MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTF2Lkm1OUDPxE1? M1u5OnNCVkeHUh?=
OCUB-M M{nN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37CXWlEPTB;MUSuPVg5OyEQvF2= MUjTRW5ITVJ?
ES7 NVHrcVJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjiS5g6UUN3ME2xOU4xQTh2IN88US=> NID4ZY5USU6JRWK=
SW1463 NIK2b4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTF3LkSyNlMh|ryP M2\6[3NCVkeHUh?=
CAKI-1 NUjING9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\xTWM2OD1zNT61N|Q3KM7:TR?= MVnTRW5ITVJ?
MKN28 NF6zO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPETWM2OD1zNT61OFc6KM7:TR?= NELmVlRUSU6JRWK=
SW13 NVKzO4Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTF3Lk[xPEDPxE1? NGDNOFRUSU6JRWK=
A3-KAW NX;oUWk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnSVpBKSzVyPUG1Mlk3QTdizszN NETKNXlUSU6JRWK=
LU-65 NVq2WlhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfTWFJKSzVyPUG1Mlk4PjhizszN Mm\KV2FPT0WU
Calu-1 Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnaTWM2OD1zNj6wN|Y5KM7:TR?= NVXqeFVsW0GQR1XS
ST486 M1npfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTkbmNKSzVyPUG2MlA1OzFizszN M{TWdXNCVkeHUh?=
BB30-HNC NWPjfXk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjnTWM2OD1zNj6xNlQ3KM7:TR?= MUDTRW5ITVJ?
EGI-1 NYrv[pZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjuWmdKSzVyPUG2MlQ1PiEQvF2= MUjTRW5ITVJ?
SH-4 NVPxXlFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjhcFNKSzVyPUG2MlQ4OzFizszN M2HB[nNCVkeHUh?=
MN-60 NWLTflBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTF5LkKyPVch|ryP M1:wc3NCVkeHUh?=
MPP-89 NVXmSYtpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7sUm5KSzVyPUG3MlI1PTlizszN Mm\0V2FPT0WU
A2780 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnyUohKSzVyPUG3MlQyOzlizszN MoTvV2FPT0WU
Daoy M3Lqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG2cZhKSzVyPUG3MlQ3QTVizszN Mn;SV2FPT0WU
NCI-H2126 NVTFNG1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTF5LkS3O|Eh|ryP M1jz[3NCVkeHUh?=
NCI-H1563 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvVTWM2OD1zNz60PVE4KM7:TR?= NIXEXVBUSU6JRWK=
8-MG-BA MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2qwT2lEPTB;MUeuOlY1QCEQvF2= NVXkdoRMW0GQR1XS
786-0 M4K5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF5LkizOVMh|ryP M2XoZ3NCVkeHUh?=
AM-38 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPoWnhKSzVyPUG3Mlk{ODZizszN MlzOV2FPT0WU
COLO-824 M{npWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInvV|BKSzVyPUG4MlQ1OzZizszN MmriV2FPT0WU
SK-MEL-30 NGq3UmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXLdZZKSzVyPUG4MlUxQDJizszN NV;UW2d[W0GQR1XS
CESS NHnYO|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTYWlRZUUN3ME2xPE44PjB7IN88US=> MX7TRW5ITVJ?
BL-70 NHHQO25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3uxTGlEPTB;MUiuPFE2PiEQvF2= NG\iXo9USU6JRWK=
NCI-H2170 NV7mcXE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjlfFJKSzVyPUG4MlkyPzlizszN MXzTRW5ITVJ?
HT-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTJcGxKSzVyPUG4Mlk5OyEQvF2= NIjTWIxUSU6JRWK=
BOKU NV3LTIVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF7LkCzPFEh|ryP NV;l[3NIW0GQR1XS
HPAF-II M4DUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTF7LkOwNVUh|ryP MYjTRW5ITVJ?
KGN MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvSTWM2OD1zOT60O|Y2KM7:TR?= M4H3eHNCVkeHUh?=
MC-CAR M33sSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljxTWM2OD1zOT62N|E{KM7:TR?= M{S0WHNCVkeHUh?=
BHT-101 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDhRndKSzVyPUG5Mlc4PyEQvF2= MV3TRW5ITVJ?
SW1783 MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4SxRWlEPTB;MUmuO|gxPiEQvF2= NHfZfFBUSU6JRWK=
KP-N-YN NVrSNoVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJyLkCyOlIh|ryP M4PrTXNCVkeHUh?=
LU-165 NXOxO2pTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Pk[mlEPTB;MkCuOVU4OSEQvF2= M1;1NHNCVkeHUh?=
GOTO NITDZWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHriNWhKSzVyPUKwMlY1PTFizszN M1OxSnNCVkeHUh?=
EFM-19 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn4TWM2OD1{MT6wO|E3KM7:TR?= MV7TRW5ITVJ?
CTV-1 NV\oclFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rIVGlEPTB;MkGuNVA2PCEQvF2= MmjFV2FPT0WU
HEL M4Phcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWOyUm1wUUN3ME2yNU41OjF4IN88US=> NGS5UXlUSU6JRWK=
SNU-C2B MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3L0XWlEPTB;MkGuOFI3KM7:TR?= MV;TRW5ITVJ?
ECC4 NH62bm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XpZWlEPTB;MkGuO|A4KM7:TR?= NUXZNpo6W0GQR1XS
NEC8 NGD3NFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnOTWM2OD1{MT64N|Y5KM7:TR?= NULuOVBDW0GQR1XS
KMOE-2 NVLVbWg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK1dGhKSzVyPUKxMlg6OjFizszN M2fobHNCVkeHUh?=
NCI-H524 NF:ydmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJ{LkC4NFgh|ryP Mn\UV2FPT0WU
WSU-NHL NGfhcFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXK[49VUUN3ME2yNk4yPTd5IN88US=> MXHTRW5ITVJ?
SF126 M3na[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlX0TWM2OD1{Mj6yOFY6KM7:TR?= NXiwZ2FYW0GQR1XS
HOP-92 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnSOllxUUN3ME2yNk4{OTZ5IN88US=> NX31PYRrW0GQR1XS
CTB-1 MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vMZWlEPTB;MkKuOFY4PyEQvF2= MXnTRW5ITVJ?
KYSE-270 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\KTWM2OD1{Mj65N|U4KM7:TR?= MmjjV2FPT0WU
SK-MEL-24 MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD2fVFQUUN3ME2yN{4yQDdizszN MXTTRW5ITVJ?
Calu-3 M{\i[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS4O5NYUUN3ME2yN{4zOTJ6IN88US=> NEnoTlNUSU6JRWK=
GAMG MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;DdFlKSzVyPUKzMlI{PjdizszN MlvvV2FPT0WU
SW1573 MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37mbWlEPTB;MkOuO|QyPSEQvF2= M4POc3NCVkeHUh?=
MHH-NB-11 MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXZd3RKSzVyPUK0MlAyQTRizszN MVvTRW5ITVJ?
TK10 NVjMbpc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDpWGNKSzVyPUK0MlUxOTNizszN MY\TRW5ITVJ?
LB373-MEL-D NF7KeVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXOTWM2OD1{ND62NFY1KM7:TR?= NUXIZ4NQW0GQR1XS
KALS-1 NYXremEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LuWGlEPTB;MkSuO|MzPyEQvF2= MY\TRW5ITVJ?
HUTU-80 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\TTWM2OD1{NT64NFMzKM7:TR?= M1K5fnNCVkeHUh?=
HuP-T3 M4jaSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlixTWM2OD1{Nj6xOlc1KM7:TR?= NWPC[mw{W0GQR1XS
OE19 NUPz[HR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTJ4LkKxOVMh|ryP NFrINWtUSU6JRWK=
J82 M4e5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrKR4loUUN3ME2yOk4zPDdzIN88US=> MWHTRW5ITVJ?
DU-4475 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTOTWM2OD1{Nj6zPFE6KM7:TR?= NWnmfWw5W0GQR1XS
DMS-53 M4DUWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7VSWxKSzVyPUK2MlUyOzhizszN M1LYRXNCVkeHUh?=
COLO-741 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfmPWhKSzVyPUK2Mlg{PDRizszN Ml3UV2FPT0WU
SW48 M13hfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVm3To5TUUN3ME2yOk45QDJizszN MXfTRW5ITVJ?
IGR-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJ4LkmzN|Qh|ryP NWPGVmNQW0GQR1XS
639-V M2rPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7HTWM2OD1{Nz6wNlQ2KM7:TR?= M3zaeHNCVkeHUh?=
LK-2 M4qxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHr[ndKSzVyPUK3MlQyPDFizszN MnzsV2FPT0WU
NCI-H2347 NGfmO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO3TWM2OD1{Nz65Olk6KM7:TR?= MXzTRW5ITVJ?
NCI-H2228 NHjsbnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHBTWM2OD1{OD6wPVA2KM7:TR?= MV7TRW5ITVJ?
LS-123 M{LFN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M361bmlEPTB;MkiuNVI3OiEQvF2= Mk\GV2FPT0WU
U031 M1HMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJ6LkK1NkDPxE1? M4rDVHNCVkeHUh?=
NCI-H1792 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jVRmlEPTB;MkiuOFczOSEQvF2= MVfTRW5ITVJ?
NCI-H2087 NEPkcZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjxTWM2OD1{OD63OVUzKM7:TR?= MorkV2FPT0WU
NCI-H2342 M4DT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTHZYt2UUN3ME2yPU42OjB6IN88US=> MXzTRW5ITVJ?
SW626 Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJ7Lke1OkDPxE1? MXLTRW5ITVJ?
LB2518-MEL NWDGXYRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHkbFA2UUN3ME2yPU45OTVizszN NYLxbmNQW0GQR1XS
RXF393 MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTNyLkC5OVIh|ryP MlmzV2FPT0WU
LC4-1 M3SwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NImxU2dKSzVyPUOwMlMxQTJizszN M{P0ZXNCVkeHUh?=
NCI-H1694 NUK0NoVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHFTWM2OD1|MD62OlI1KM7:TR?= M4P2TXNCVkeHUh?=
K5 NE[2UZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTNyLkm3NFIh|ryP NYjYN|FFW0GQR1XS
HDLM-2 NFXlb29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7GSWtKSzVyPUOwMlk4OjVizszN M13vTnNCVkeHUh?=
BCPAP NXr4S4plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjJTWM2OD1|MT64N|c6KM7:TR?= NIXNeHNUSU6JRWK=
BC-3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz4WFVyUUN3ME2zNk4yPDB|IN88US=> NYLjfFlVW0GQR1XS
LB996-RCC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;KO5dKSzVyPUOyMlI{PThizszN NGjudlVUSU6JRWK=
NCI-H2009 NVfXWJl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zCUmlEPTB;M{KuOFk5OSEQvF2= NI[4TnBUSU6JRWK=
HTC-C3 M{j1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC4TWM2OD1|Mz63OVE6KM7:TR?= NXP4OZdCW0GQR1XS
LAMA-84 MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmThTWM2OD1|ND60OFA4KM7:TR?= MlvEV2FPT0WU
CCRF-CEM MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTN2LkW3NVUh|ryP MY\TRW5ITVJ?
AN3-CA M1vOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTsNIRKSzVyPUO1MlA2PjhizszN NXrjR|czW0GQR1XS
NCI-H1734 NYrpRohLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3STWM2OD1|NT6yOVYyKM7:TR?= M1L4XnNCVkeHUh?=
Ca-Ski NHO1[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPoWW05UUN3ME2zOU41OTBzIN88US=> NIfwPIJUSU6JRWK=
U-266 NE\hUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17SWGlEPTB;M{WuOlEyPCEQvF2= M2q5OHNCVkeHUh?=
SBC-5 MmH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fv[GlEPTB;M{WuO|c5OSEQvF2= M3\PRXNCVkeHUh?=
GT3TKB NXPZSVdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXBNHdyUUN3ME2zO{4yOTVizszN MoK0V2FPT0WU
MDA-MB-175-VII NV\pbodjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTN5LkKyOFgh|ryP MnfyV2FPT0WU
PFSK-1 M3\seWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu2NpFKSzVyPUO3MlI1OzVizszN M4HyUHNCVkeHUh?=
IMR-5 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PSNGlEPTB;M{euNlQ5PyEQvF2= MoHOV2FPT0WU
Daudi NEK1[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj1dXJKSzVyPUO3MlM2QTdizszN MXXTRW5ITVJ?
A498 NUPBPIhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPRUFlMUUN3ME2zO{44OjF6IN88US=> M3\RbHNCVkeHUh?=
SCC-4 NVLKZpJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmS3TWM2OD1|Nz63PFQ{KM7:TR?= NX20fYZCW0GQR1XS
COLO-680N M{LCV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXL1W3VjUUN3ME2zPE4zQDh3IN88US=> MYHTRW5ITVJ?
SK-MES-1 NVjZWYJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHZTWM2OD1|OD6zNlE2KM7:TR?= MYXTRW5ITVJ?
SR MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTN6LkW0PVUh|ryP NXLVR5JGW0GQR1XS
LNCaP-Clone-FGC M3Lk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:5S2lEPTB;M{iuOVY{PyEQvF2= M2LTTnNCVkeHUh?=
SK-HEP-1 M4jSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf6OXFKSzVyPUO4Mlc5OjJizszN NIT1bFVUSU6JRWK=
BPH-1 M{T6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnO1TWM2OD1|OD64N|I6KM7:TR?= MlezV2FPT0WU
NCI-H1755 MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTN7LkW4NVch|ryP MnfCV2FPT0WU
LXF-289 M4fnd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDGVpZKSzVyPUO5MlgxQDRizszN NXG1Z29PW0GQR1XS
SW1088 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPiTWM2OD12MD6yNVA4KM7:TR?= NV\pPJY5W0GQR1XS
MOLT-4 NULhU202T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGj3WndKSzVyPUSwMlI6ODFizszN MorHV2FPT0WU
AsPC-1 NHvjXHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7ndo9KSzVyPUSwMlQ2QDNizszN MnLCV2FPT0WU
HOP-62 NVyySJJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe4bFBUUUN3ME20NE43PTZ6IN88US=> Mnn2V2FPT0WU
A172 NIDWWW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7DVWxKSzVyPUSwMlg2OTFizszN NWT4[3M5W0GQR1XS
SN12C NEDDbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLucmpqUUN3ME20NE46Ozh3IN88US=> MVHTRW5ITVJ?
MDA-MB-231 NXHOc2MzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfFW|hWUUN3ME20NE46QDl6IN88US=> NXfKS2JkW0GQR1XS
RPMI-2650 MofHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\MNlNbUUN3ME20NU4yPTl|IN88US=> M{DYdXNCVkeHUh?=
KYSE-140 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PSVWlEPTB;NEGuPFEzOyEQvF2= MVHTRW5ITVJ?
KINGS-1 NX;yTJJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGThPGRKSzVyPUSyMlQ3QTdizszN MX\TRW5ITVJ?
HSC-3 M{Dq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXYZYxKSzVyPUSyMlY3PjFizszN NWjmZlJDW0GQR1XS
PC-14 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTR|LkG4PFIh|ryP NHLsdpVUSU6JRWK=
COR-L105 MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHMb5FKSzVyPUSzMlY2ODJizszN NWPEU|g2W0GQR1XS
BE-13 M3Lxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\YTWM2OD12ND6yN|cyKM7:TR?= NVzUSGV5W0GQR1XS
NCI-H661 NV;lfmozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnS0TWM2OD12ND6yPVU5KM7:TR?= M4PUcnNCVkeHUh?=
IST-MEL1 MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzKcWRKSzVyPUS0MlM2QTlizszN M1\RT3NCVkeHUh?=
HCC1806 NHz0[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKwS5BKSzVyPUS0MlU5PzNizszN NUDvNJo6W0GQR1XS
COLO-800 NUPufW1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfCfpl{UUN3ME20OE45PDV|IN88US=> MoC3V2FPT0WU
IST-SL2 NYXiUGRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nrPWlEPTB;NEWuNVI1PyEQvF2= M4rsbnNCVkeHUh?=
8305C M2rGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTR3LkOwPUDPxE1? MW\TRW5ITVJ?
UACC-62 NWnPPXBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFS3dZBKSzVyPUS2MlI5PzVizszN NGX2Z2NUSU6JRWK=
COR-L23 Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XkR2lEPTB;NEeuNVk6KM7:TR?= NIfrNYdUSU6JRWK=
EFE-184 NIHEPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XzdGlEPTB;NEeuN|g5KM7:TR?= NYjN[mt3W0GQR1XS
DMS-114 NWi5WZBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT2NJhKSzVyPUS3MlQyPDlizszN MmT2V2FPT0WU
KYSE-520 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUKwXo56UUN3ME20PE42OzF3IN88US=> MVfTRW5ITVJ?
SNG-M NX;Gc|NkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fuVmlEPTB;NEmuOFM1KM7:TR?= NELaTHRUSU6JRWK=
A2058 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHNeoNYUUN3ME20PU41QDh3IN88US=> MY\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay
+ Expand

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research
+ Expand
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG 400+0.5% Tween 80+5% Propylene glycol 30mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Active, not recruiting Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy OSI-906 (Linsitinib) | OSI-906 (Linsitinib) supplier | purchase OSI-906 (Linsitinib) | OSI-906 (Linsitinib) cost | OSI-906 (Linsitinib) manufacturer | order OSI-906 (Linsitinib) | OSI-906 (Linsitinib) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID